Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Mouse, Rat|
|Published species reactivity||Rat, Human|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Synthetic peptide corresponding to residues 3-14 of the human bcl-xl.|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||1 - 5 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for this product is human, mouse or rat thymocytes.
Bcl2 family is a key regulator of apoptosis that functions to either inhibit or promote cell death. Over-expression of members such as Bcl2 and BclxL inhibit the apoptotic process. The Bcl2 family members are also characterized by dimerizing to further modulate apoptosis. Bag1, for example, has been found to form a heterodimer with Bcl2 resulting in the enhancement of the anti-apoptotic effect of Bcl2. Bax and Bak have been shown to play a critical role in cytochrome c release from mitochondria and thus initiate apoptosis. Bax exerts a pro-apoptotic rather than an anti-apoptotic effect on cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
MA1-12241 was used in western blot to examine the anti-apoptotic role of Bcl-xL and myeloid cell leukaemia-1 in colorectal cancer cells
|Schulze-Bergkamen H,Ehrenberg R,Hickmann L,Vick B,Urbanik T,Schimanski CC,Berger MR,Schad A,Weber A,Heeger S,Galle PR,Moehler M||World journal of gastroenterology (14:3829)||2008|
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
MA1-12241 was used in western blot to examine the hepatotoxicity of TRAIL/bortezomib cotreatment
|Koschny R,Ganten TM,Sykora J,Haas TL,Sprick MR,Kolb A,Stremmel W,Walczak H||Hepatology (Baltimore, Md.) (45:649)||2007|
Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria.
MA1-12241 was used in western blot to study the role of Bcl-2 and mitochrondria in the neuroprotective effects of minocycline
|Wang J,Wei Q,Wang CY,Hill WD,Hess DC,Dong Z||The Journal of biological chemistry (279:19948)||2004|
Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.
MA1-12241 was used in immunohistochemistry to investigate the role of Epstein-Barr virus infection in the immune response of non-monomorphic post-transplant lymphoproliferative disorders
|Shaknovich R,Basso K,Bhagat G,Mansukhani M,Hatzivassiliou G,Murty VV,Buettner M,Niedobitek G,Alobeid B,Cattoretti G||Haematologica (91:1313)||2006|
Increased apoptosis in human osteoarthritic cartilage corresponds to reduced cell density and expression of caspase-3.
MA1-12241 was used in immunohistochemistry to investigate cell death in osteoarthritic cartilage and the role of caspase-3 during this process
|Sharif M,Whitehouse A,Sharman P,Perry M,Adams M||Arthritis and rheumatism (50:507)||2004|
Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays.
MA1-12241 was used in immunohistochemistry (paraffin) to study alterations in tumor suppressor pathways and cell cycle checkpoints in Hodgkin and Reed-Sternberg cells.
|García JF,Camacho FI,Morente M,Fraga M,Montalbán C,Alvaro T,Bellas C,Castaño A,Díez A,Flores T,Martin C,Martinez MA,Mazorra F,Menárguez J,Mestre MJ,Mollejo M,Sáez AI,Sánchez L,Piris MA||Blood (101:681)||2003|
BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus.
MA1-12241 was used in immunohistochemistry to determine the organization and expression of BCL-6 in normal and neoplastic thymic T cells.
|Hyjek E,Chadburn A,Liu YF,Cesarman E,Knowles DM||Blood (97:270)||2001|
anti-apoptosis regulatory protein; apoptosis regulator Bcl-X; B cell lymphoma 2 like; B cell lymphoma like X; B-cell leukemia/lymphoma x; bcl-2 L1; bcl-2-like protein 1; Bcl-X; BCL-XL/S; bcl-xS; bcl2-L-1; BCL2L; BCLX; DKFZp781P2092
Bcl(X)L; bcl-X; Bcl-XL; bcl2-L-1; Bcl2l; Bcl2l1; BclX; Blc2l